|
15 Jan 2020 |
Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase
|
|
15 Jan 2020 |
Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
|
|
13 Jan 2020 |
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
|
|
13 Jan 2020 |
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
|
|
13 Jan 2020 |
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
|
|
13 Jan 2020 |
Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia
|
|
13 Jan 2020 |
LYNPARZA® (olaparib) regulatory submission granted priority review in US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
|
|
12 Jan 2020 |
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
|
|
12 Jan 2020 |
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
|
|
12 Jan 2020 |
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
|
|
12 Jan 2020 |
Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
|
|
10 Jan 2020 |
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
|
|
09 Jan 2020 |
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
|
|
09 Jan 2020 |
Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
|
|
09 Jan 2020 |
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
|
|
09 Jan 2020 |
AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise
|
|
09 Jan 2020 |
OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
|
|
08 Jan 2020 |
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
|
|
08 Jan 2020 |
Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
|
|
08 Jan 2020 |
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
|
|
07 Jan 2020 |
Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
|
|
07 Jan 2020 |
AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain
|
|
07 Jan 2020 |
InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab
|
|
07 Jan 2020 |
Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis
|
|
07 Jan 2020 |
Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
|
